arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

GLAUKOS Corp

GKOS
$220.01 ▼ -26.47 (-10.74%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
14 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
18
Health
Poor
Bearish
auto_awesome

Analytical Summary

GLAUKOS Corp faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $12.6B
Dividend Yield —
Revenue Growth 32.3% ↗
Op. Margin -39.3% ↘
ROIC -29.6% ↘
FCF / Share $-0.39 ↗
Trailing P/E —
Price / Book 19.3x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

14-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$507.44M
↑ +32.3% —
Net Income Profit after all expenses
$-187.69M
↓ -28.2% —
Operating Margin Operating profit as % of sales
-39.3%
↓ -23.3% 6th
FCF / Share Free cash flow per share
$-0.39
↑ +69.4% —
Long-Term Debt Long-term obligations
$9.70M
↓ -44.6% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↓
10
Returns ↓
24
Financial Health ↓
18
Cash Quality ↓
26

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 14 years · 53 quarters